Ann: Termination of Mr Daniel Kenny as Chief Executive Officer, page-2

Termination of Mr Daniel Kenny as Chief Executive Officer
Sydney, Australia – 2 December 2020: The Board of OncoSil Medical Ltd (ASX: OSL) (OncoSil or the
Company) announces that its Chief Executive Officer, Mr. Daniel Kenny, has been terminated effective
today. The Board would like to thank Daniel for his services and contribution to OncoSil over the last 6
years.
As the Board undertakes a process for Daniel Kenny’s replacement, OncoSil’s current Chairman, Dr. Chris
Roberts, will step into the role of Executive Chairman. Dr Roberts has been Chairman of OncoSil since
May 2017.
Since the approval of the CE Mark on 1 April, the Company has progressed many of the necessary launch
preparations for first sales in Europe, however first European revenues are unlikely to occur by the end of
calendar 2020 as previously forecast. The Board is working directly with Nigel Lange (President EMEA) and
the executive team and will update expectations in due course.

Happy Days, here we go.